Post by account_disabled on Mar 13, 2024 2:27:33 GMT -6
The Russian Direct Investment Fund (RDIF) and the Gamaleya Research Institute (part of the Russian Ministry of Health) have announced that preliminary data from clinical trials of their Covid-19 vaccine, Sputnik V , shows effective 91.4% after days from the first dose and above 95% after 42 days. This vaccine candidate was approved just two months after human trials began – in June – and raised suspicions among experts due to the speed of these tests and the opacity of the data on this drug. Both Russian institutions have announced that each dose will cost less than ten dollars in international markets. As it is a two-dose vaccine, its price will be below $20 , “two or more times cheaper than other foreign vaccines based on messenger RNA technology [Moderna and Pfizer] with similar efficacy ratios,” they have pointed out. it's a statement. This vaccine will be free for Russian citizens. This vaccine is a combination of two adenoviruses, Ad5 and Ad26, both designed with a coronavirus gene The RDIF has agreed to start the production of this “dehydrated” vaccine using freeze-drying technology.
In this way, they say, "it will be stored at temperatures of 2 to 8 ºC , which will facilitate transportation to international markets, even to regions with difficult access and tropical climates." The goal of the Russian fund is to distribute the vaccine to 500 million people from the beginning of 2021. The vaccine, whose technical name is Gam-Covid-Vac Lyo (and renamed after the Soviet satellite), is a combination of two adenoviruses , Ad5 and Ad26, both engineered AOL Email List with a gene from the coronavirus. The general director of the RDIF, Kirill Dmitriev , has highlighted that the vaccine developed by the Gamaleya Institute is “unique” due to the use of two different human adenoviral vectors “that allow a stronger and longer-lasting immune response compared to vaccines that use a single vector [Oxford-AstraZeneca]”. “We are prepared to ship the Sputnik V vaccine to international markets thanks to agreements with manufacturers in India, Brazil, South Korea.
China and four other countries,” Dmitriev concluded. Data from your clinical trial As of today, the RDIF and the Gamaleya Institute have announced in a statement that they have tested the vaccine on some 40,000 volunteers have received the first dose, while 19,000 people already have the second. Some 40,000 volunteers have tested the vaccine: have received the first dose, while 19,000 people already have the second In this document, both institutions assure that phase III clinical trials are “approved and ongoing” in Belarus, the United Arab Emirates, Venezuela and other countries, while a phase II-III trial is being carried out in India. According to these data, no adverse effects have been identified from this vaccine throughout the research, although some volunteers have suffered minor conditions such as pain in the injection area and flu-like symptoms such as fever, weakness, fatigue and sore throat.
In this way, they say, "it will be stored at temperatures of 2 to 8 ºC , which will facilitate transportation to international markets, even to regions with difficult access and tropical climates." The goal of the Russian fund is to distribute the vaccine to 500 million people from the beginning of 2021. The vaccine, whose technical name is Gam-Covid-Vac Lyo (and renamed after the Soviet satellite), is a combination of two adenoviruses , Ad5 and Ad26, both engineered AOL Email List with a gene from the coronavirus. The general director of the RDIF, Kirill Dmitriev , has highlighted that the vaccine developed by the Gamaleya Institute is “unique” due to the use of two different human adenoviral vectors “that allow a stronger and longer-lasting immune response compared to vaccines that use a single vector [Oxford-AstraZeneca]”. “We are prepared to ship the Sputnik V vaccine to international markets thanks to agreements with manufacturers in India, Brazil, South Korea.
China and four other countries,” Dmitriev concluded. Data from your clinical trial As of today, the RDIF and the Gamaleya Institute have announced in a statement that they have tested the vaccine on some 40,000 volunteers have received the first dose, while 19,000 people already have the second. Some 40,000 volunteers have tested the vaccine: have received the first dose, while 19,000 people already have the second In this document, both institutions assure that phase III clinical trials are “approved and ongoing” in Belarus, the United Arab Emirates, Venezuela and other countries, while a phase II-III trial is being carried out in India. According to these data, no adverse effects have been identified from this vaccine throughout the research, although some volunteers have suffered minor conditions such as pain in the injection area and flu-like symptoms such as fever, weakness, fatigue and sore throat.